SCHEMBL7370339

SCHEMBL7370339

O=C(O)c1cc2c(cc1C(=O)O)OCO2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
MAPK1 P28482 2/20 0.57
SMN1; SMN2 Q16637 4/20 0.52
SRD5A2 P31213 1/20 0.50
CYP1A2 P05177 3/20 0.45
KDM4E B2RXH2 3/20 0.45
CTNNB1 P35222 2/20 0.45
CYP2D6 P10635 1/20 0.45
HPGD P15428 1/20 0.45
APEX1 P27695 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
TP53 P04637 2/20 0.44
DHODH Q02127 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 2/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29921207 1.00 ALDH1A1 (0.57) ALDH1A1MAPK1SMN1; SMN2SRD5A2CYP1A2
SCHEMBL4110874 0.88 ALDH1A1 (0.47) ALDH1A1MAPK1SMN1; SMN2SRD5A2CYP1A2
SCHEMBL5391668 0.87 CTNNB1 (0.55) ALDH1A1MAPK1SMN1; SMN2SRD5A2CYP1A2
SCHEMBL29828929 0.87 CTNNB1 (0.55) ALDH1A1MAPK1SMN1; SMN2SRD5A2CYP1A2
SCHEMBL7275882 0.85 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL4472381 0.85 ALDH1A1 (0.48) ALDH1A1MAPK1SMN1; SMN2SRD5A2CYP1A2
SCHEMBL31360301 0.85 ALDH1A1 (0.53) ALDH1A1MAPK1SMN1; SMN2SRD5A2CYP1A2
SCHEMBL7216296 0.85 SMN1; SMN2 (0.73) ALDH1A1MAPK1SMN1; SMN2SRD5A2CYP1A2
SCHEMBL711100 0.85 ALDH1A1 (0.53) ALDH1A1MAPK1SMN1; SMN2SRD5A2CYP1A2
SCHEMBL7018429 0.85 ALDH1A1 (0.50) ALDH1A1MAPK1SMN1; SMN2SRD5A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023512-B2 Production of organic materials using oxidative hydrothermal dissolution method SOUTHERN ILLINOIS UNIVERSITY CARBONDALE (US) 2018-07-17 US disclosed
CN-103764804-A Production of organic materials using oxidative hydrothermal dissolution process SOUTHERN ILLINOIS UNIVERSITY CARBONDALE 2014-04-30 CN disclosed
US-20120289695-A1 PRODUCTION OF ORGANIC MATERIALS USING OXIDATIVE HYDROTHERMAL DISSOLUTION METHOD SOUTHERN ILLINOIS UNIVERSITY CARBONDALE (US) 2012-11-15 US disclosed
US-7393625-B2 Photothermographic material FUJIFILM CORPORATION (JP) 2008-07-01 US disclosed
US-7393625-B2 Photothermographic material FUJIFILM CORPORATION (JP) 2008-07-01 US disclosed
EP-1840646-A1 Photothermographic material FUJIFILM Corporation (JP) 2007-10-03 EP disclosed
US-20070224555-A1 Photothermographic material FUJIFILM CORPORATION 2007-09-27 US disclosed
US-20070224555-A1 Photothermographic material FUJIFILM CORPORATION 2007-09-27 US disclosed
EP-0790974-B1 SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS BAYER AG (US) 2002-08-14 EP disclosed
US-6166082-A Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors BAYER CORPORATION (US) 2000-12-26 US disclosed
US-5789434-A ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION BAYER CORPORATION (US) 1998-08-04 US disclosed
EP-0790974-A1 SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS Bayer Corporation (US) 1997-08-27 EP disclosed
WO-1996015096-A1 SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS BAYER CORPORATION (US) 1996-05-23 WO disclosed
EP-0334172-A1 Reactive dyes BAYER AG (DE) 1989-09-27 EP disclosed
EP-0198522-A1 Heterocyclic herbicides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1986-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289695-A1 PRODUCTION OF ORGANIC MATERIALS USING OXIDATIVE HYDROTHERMAL DISSOLUTION METHOD HAO2, HPD, AOC2 ALDH1A1 569/4885MAPK1 3196/4885SMN1; SMN2 4675/4885
US-10023512-B2 Production of organic materials using oxidative hydrothermal dissolution method HAO2, HPD, AOC2 ALDH1A1 569/4885MAPK1 3196/4885SMN1; SMN2 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.